Literature DB >> 22329848

A subpopulation of CD24⁺ cells in colon cancer cell lines possess stem cell characteristics.

J Ke1, X Wu, X Wu, X He, L Lian, Y Zou, X He, H Wang, Y Luo, L Wang, P Lan.   

Abstract

Cancer stem cells (CSCs) have been shown to contribute to the resistance and relapse in a range of cancer types such as breast cancer and glioma. However, colon cancer stem cells remain poorly characterized. Here we reported that CD24+ subpopulation in colon cancer cell lines HCT116 and SW480 exhibited cancer stem cell-like characteristics. Using flow cytometry candidate CSCs markers were selected after initial screening of known CSCs markers from other types of cancer on colon cancer cell lines HCT116, SW480 and HT29. CD24 was expressed in the minority of bulk cell population of HCT116 and SW480 cell lines. Moreover, functional tests demonstrated that CD24+ cells exhibited enhanced chemotherapy-resistance, self-renewal and tumorigenic capacity both in vitro and in vivo, compared to CD24- subpopulations. These results suggest that CD24+ subpopulation in colon cancer cell lines HCT116 and SW480 exhibits CSCs like characteristics, and represents a nice model to study and develop effective strategies to overcome chemo-resistance and relapse of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22329848     DOI: 10.4149/neo_2012_036

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  20 in total

1.  CD24 genetic variants contribute to overall survival in patients with gastric cancer.

Authors:  Zhi-Fang Jia; Li-Zhong Wang; Xue-Yuan Cao; Chuan Wang; Dong-Hui Cao; Xing Wu; Li-Li You; Mei-Shan Jin; Yin-Ping Wang; Bao-Sen Zhou; Jing Jiang
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

2.  Antitumor effects of matrine on cancer stem like cells isolated from the human liver cancer SMMC-7721 cell line.

Authors:  Yong Wang; Yahui Liu; Jianshuai Jiang; Hanbin Cui
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

3.  Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features.

Authors:  H Was; J Czarnecka; A Kominek; K Barszcz; T Bernas; K Piwocka; B Kaminska
Journal:  Cancer Biol Ther       Date:  2017-12-22       Impact factor: 4.742

Review 4.  Hypoxia and regulation of cancer cell stemness.

Authors:  Zhong Yun; Qun Lin
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 5.  Advances in Liver Cancer Stem Cell Isolation and their Characterization.

Authors:  Lu Liu; Jürgen Borlak
Journal:  Stem Cell Rev Rep       Date:  2021-01-11       Impact factor: 5.739

6.  Colon Crypts of Subjects With Familial Adenomatous Polyposis Show an Increased Number of LGR5+ Ectopic Stem Cells.

Authors:  Lucas T Jennelle; Christopher H Dampier; Stephanie Tring; Steven Powell; Graham Casey
Journal:  Clin Transl Gastroenterol       Date:  2021-05-17       Impact factor: 4.396

7.  Establishment and characterization of a novel cell line derived from thymoma with myasthenia gravis patients.

Authors:  Guojin Wang; Yuanguo Wang; Peng Zhang; Yuan Chen; Yimei Liu; Feng Guo; Hui Zhang
Journal:  Thorac Cancer       Date:  2015-03-02       Impact factor: 3.500

8.  Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells.

Authors:  Sara Häggblad Sahlberg; Diana Spiegelberg; Bengt Glimelius; Bo Stenerlöw; Marika Nestor
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

9.  Hypoxia-inducible factors modulate the stemness and malignancy of colon cancer cells by playing opposite roles in canonical Wnt signaling.

Authors:  Paula Santoyo-Ramos; María Likhatcheva; Eduardo A García-Zepeda; M Cristina Castañeda-Patlán; Martha Robles-Flores
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

Review 10.  Self-renewal molecular mechanisms of colorectal cancer stem cells.

Authors:  Tianhui Pan; Jinghong Xu; Yongliang Zhu
Journal:  Int J Mol Med       Date:  2016-11-30       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.